Global Malabsorption Syndrome Market Size, Share, Forecast Report, 2020-2027

Global Malabsorption Syndrome Market is expected to grow at a CAGR of 11.0% during the forecast period of 2017-2023. Malabsorption syndrome is the poor absorption of fat, vitamins, carbohydrate, protein, and other nutrients from the intestinal tract into the bloodstream. The possible major causes of malabsorption syndrome are prolonged use of antibiotics, Celiac disease, Cystic fibrosis, Crohn’s disease, lactose intolerance, parasitic diseases, diseases of the gallbladder or liver, and intestinal inflammation.

It is noted that rising cases of causative diseases such as celiac disease, and others is the key factor driving the malabsorption syndrome market. Celiac disease is a serious autoimmune disorder, and is estimated to affect 1 in 100 people worldwide, suggested by Celiac Disease Foundation.

Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global malabsorption syndrome market.

Despite these drivers, there are some issues associated with malabsorption syndrome market. The side effects of drugs and other therapeutic agents, infections, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.
Segmentation:

The global malabsorption syndrome market is segmented on the basis of diagnosis, causative diseases, treatment, and end user.

On the basis of the diagnosis, the market is classified as hematologic tests, imaging studies, and other tests. The imaging studies segment is classified as CT scan, magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatogram (ERCP), and abdominal X-ray. The other tests segment is classified as test of fat malabsorption, D-xylose test, tests of carbohydrate absorption, test of bile salt absorption, schilling test, and C-D-xylose breath test.

On the basis of the causative diseases, the market is classified as lactose intolerance, cystic fibrosis, Whipple’s disease, parasitic diseases, tropical sprue, intestinal disorders, and others. The Intestinal disorders segment is further classified as Celiac disease, and others.

On the basis of the treatment, the market is classified as nutritional supplements, gluten-free diet, protease and lipase supplements, antibiotics, antidiarrheal agents, anti-inflammatory drugs, and others.

On the basis of the end user, the market is segmented into pharmaceutical companies, Hospitals, Nutrition Clinics, Academic and Research Institutes, and others.
Key Players:

Some of key the players in the global malabsorption syndrome market are Abbvie, Inc., Actelion Pharmaceuticals Ltd, AstraZeneca PLC, Bayer Healthcare AG, DSM, Eli Lily and Company, Gilead Sciences, GlaxoSmithKline plc, Glenmark Pharmaceuticals, KLAIRE LABORATORIES, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, McNeil Nutritionals, National Enzyme Company, Perrigo, Pfizer, Inc., Roche, Sanofi, Vetbiochem India Private Limited, and others.